Journal of Immunology Research / 2016 / Article / Tab 1 / Research Article
The Polymorphism −308G/A of Tumor Necrosis Factor-α Gene Modulates the Effect of Immunosuppressive Treatment in First Kidney Transplant Subjects Who Suffer an Acute Rejection Table 1 Characteristics of the two randomly divided cohorts of kidney recipients.
Discovery cohort ( Validation cohort ( Recipient age, years, mean ± SD 52.2 ± 13.5 51.8 ± 13.0 0.78 Male recipient, 191 (66.8%) 100 (65.4%) 0.76 Time on dialysis, months 17.8 (7.1–31.2) 16.8 (6.1–26.9) 0.58 Cause of chronic renal failure, 0.08 Glomerulonephritis 86 (30.1%) 53 (34.6%) Chronic tubulointerstitial nephropathy 31 (10.8%) 23 (15.0%) Nephroangiosclerosis 22 (7.7%) 11 (7.2%) Polycystic kidney disease 45 (15.3%) 21 (13.7%) Diabetic nephropathy 42 (14.7%) 8 (5.2%) Unknown cause 48 (16.8%) 32 (20.9%) Others 12 (4.2%) 5 (3.3%) Donor age, years, mean ± SD 43.0 ± 14.3 42.6 ± 14.1 0.73 Male donor, 209 (73.6%) 112 (74.2%) 0.90 Donor type, 0.65 Brain death 111 (38.8%) 56 (36.6%) Circulatory death 175 (61.2%) 97 (61.2%) Immunosuppressive treatment, 0.87 Thymoglobulin + FK + MMF + P 98 (34.3%) 54 (35.3%) IL2R + FK + MMF + P 127 (44.4%) 69 (45.1%) FK + MMF + P 54 (18.9%) 28 (18.3%) CsA + MMF + P 2 (0.7%) 0 (0) FK + SRL + P 1 (0.3%) 1 (0.7%) Belatacept + MMF + P 4 (1.4%) 1 (0.7%) Follow-up time, months (median [IQR]) 74.9 (53.8–99.5) 73.0 (50.2–97.5) 0.54 Delayed graft function, 143 (50.0%) 80 (52.3%) 0.65 HLA-A mismatch, 0.56 0 24 (8.4%) 17 (11.3%) 1 118 (41.4%) 64 (42.4%) 2 143 (50.2%) 70 (46.4 %) HLA-B mismatch, 0.55 0 12 (4.2%) 4 (2.6%) 1 112 (39.3%) 66 (43.4%) 2 161 (56.5%) 82 (53.9%) HLA-DR mismatch, 0.13 0 34 (11.9%) 18 (11.8%) 1 123 (43.2%) 80 (52.6%) 2 128 (44.9%) 54 (35.5%) Acute total rejection, 80 (28.0%) 39 (25.5%) 0.58 Acute rejection Banff ≥ 2, 55 (19.2%) 28 (18.3%) 0.81 Acute humoral rejection, 20 (7.0%) 10 (6.5%) 0.86 Genotype frequency GA/AA TNF- 49 (17.1%) 26 (17.0%) 0.97 Graft loss, 49 (17.1%) 21 (13.7%) 0.35
FK: tacrolimus; MMF: mycophenolate; P: prednisone; IL2R: interleukin- (IL-) 2 receptor antagonist; CsA: cyclosporin A; SRL: sirolimus.
